Driehaus Capital Management LLC trimmed its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 14.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 696,057 shares of the company's stock after selling 115,623 shares during the period. Driehaus Capital Management LLC owned about 2.34% of Eliem Therapeutics worth $4,949,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in ELYM. Rhumbline Advisers bought a new stake in shares of Eliem Therapeutics during the 2nd quarter worth $59,000. Dimensional Fund Advisors LP purchased a new stake in shares of Eliem Therapeutics during the second quarter valued at $89,000. Bank of New York Mellon Corp acquired a new position in shares of Eliem Therapeutics in the 2nd quarter valued at $134,000. Renaissance Technologies LLC increased its stake in Eliem Therapeutics by 248.5% in the 2nd quarter. Renaissance Technologies LLC now owns 37,000 shares of the company's stock worth $263,000 after purchasing an additional 26,383 shares in the last quarter. Finally, Ally Bridge Group NY LLC acquired a new stake in Eliem Therapeutics during the 2nd quarter worth about $3,555,000. Institutional investors and hedge funds own 69.76% of the company's stock.
Insider Activity
In other news, EVP Valerie Morisset sold 69,005 shares of Eliem Therapeutics stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $8.03, for a total transaction of $554,110.15. Following the transaction, the executive vice president now owns 31,317 shares in the company, valued at $251,475.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 294,254 shares of company stock worth $2,137,260 over the last quarter. Corporate insiders own 4.70% of the company's stock.
Eliem Therapeutics Trading Up 2.2 %
ELYM stock traded up $0.11 during mid-day trading on Monday, reaching $5.09. 735,481 shares of the stock traded hands, compared to its average volume of 483,514. Eliem Therapeutics, Inc. has a 52-week low of $2.35 and a 52-week high of $11.55. The stock's fifty day moving average is $7.15 and its 200-day moving average is $6.54. The company has a market cap of $151.44 million, a P/E ratio of -9.40 and a beta of -0.35.
Eliem Therapeutics (NASDAQ:ELYM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.81) EPS for the quarter.
About Eliem Therapeutics
(
Free Report)
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
See Also
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
